InceptionR’s AbbVie ABBV Stock Holding History

InceptionR’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,811	Closed	-$1.33M	–	620
2025 Q4	$1.33M	Buy	5,811 +4,819	+486%	+$1.1M	0.37%	52
2025 Q3	$230K	Buy	+992	New	+$202K	0.06%	563
2024 Q1	–	Sell	-5,777	Closed	-$895K	–	570
2023 Q4	$895K	Buy	+5,777	New	+$842K	0.64%	3
2023 Q3	–	Sell	-8,270	Closed	-$1.11M	–	374
2023 Q2	$1.11M	Sell	8,270 -1,675	-17%	-$246K	0.59%	10
2023 Q1	$1.58M	Buy	+9,945	New	+$1.52M	0.51%	39

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

InceptionR's ABBV Position: Q1 2026 in Review

InceptionR sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 5,811 shares — an estimated $1.33M sold.

InceptionR first reported a position in ABBV in Q1 2023 and held it in 5 quarters. The position peaked at $1.58M in Q1 2023. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

InceptionR reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
InceptionR sold 5,811 AbbVie shares in Q1 2026, an estimated $1.33M.
InceptionR first reported a position in AbbVie in Q1 2023 and held it in 5 quarters.
InceptionR's AbbVie position peaked at $1.58M in Q1 2023.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on InceptionR's 13F filing for Q1 2026, filed 14 May 2026.